The company manufactures pharmaceutical products including sterile water for injections, dry powder injections, and syrups, serving major healthcare brands as a contract manufacturer and selling its own branded generics.
The company lacks a durable moat as evidenced by low net margins and a return on capital that barely exceeds the cost of capital. While it holds a WHO-GMP certification, this is a regulatory baseline rather than a competitive advantage, and the business remains a price-taking contract manufacturer in a fragmented market.
Earnings have been reinvested into expanding manufacturing capacity, specifically the commissioning of a new unit for dry powder injections. However, the negative EPS growth despite rising revenue suggests that recent capital expenditures have not yet translated into bottom-line value for shareholders.
The company's aggressive capacity expansion failed to generate incremental returns, as the dry powder injection unit became a stranded asset in a commoditized market. While revenue grew, the inability to convert paper profits into cash led to a liquidity crunch, exacerbated by an interest coverage ratio that was already failing to meet debt obligations. The disconnect between rising executive pay and cratering earnings per share eventually eroded shareholder trust, leaving the firm as a low-margin contract manufacturer unable to outrun its own working capital inefficiencies and rising cost of capital.
RichFakir rates Onyx Biotec Ltd's business quality as poor — 24/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Onyx Biotec Ltd is trading about 8% above our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Onyx Biotec Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Onyx Biotec Ltd's fair value is about ₹35 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →